Soybean Oil

證據等級: L5

預測適應症: 10 個

Soybean Oil: From Parenteral Nutrition Lipid Source to Esophageal Disease

One-Sentence Summary

Soybean oil (DrugBank DB09422) is not currently registered with SAHPRA, and no formal original indication is recorded in this evidence pack — literature consistently describes it as a component of intravenous lipid emulsions used in parenteral/enteral nutrition. Of the 10 indications the TxGNN model predicted for this drug, only Esophageal Disease (rank 4, score 98.25%) has any supporting clinical trial or literature evidence — the other 9 (including the top-ranked amenorrhea) are pure model output with zero corroborating studies. This report focuses on Esophageal Disease as the only prediction that clears an initial evidence bar, supported by 3 clinical trials and 10 publications, though the mechanistic direction of effect is inconsistent.

Quick Overview

Item	Content
Original Indication	Not recorded in regulatory data; literature context indicates use as a lipid emulsion component in parenteral/enteral nutrition (e.g. Intralipid®)
Predicted New Indication	Esophageal Disease
TxGNN Prediction Score	98.25%
Evidence Level	L4
South Africa Market Status	Not marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (marked as a High-severity data gap, DG002). Based on the available literature, soybean oil is best understood as a source of long-chain polyunsaturated fatty acids (n-3/n-6 PUFA) delivered via intravenous lipid emulsion, most often studied in the context of post-surgical nutritional support rather than as a standalone therapeutic agent.

The link to esophageal disease is indirect. Several studies included in the evidence pack examine soybean oil-based lipid emulsions given to patients undergoing esophagectomy or esophageal cancer surgery — but these look at postoperative immune and inflammatory outcomes (PMID 10024108, 22457418, 24379010), not treatment of esophageal disease itself. Separately, a distinct thread of mechanistic and animal research suggests dietary fat, including soybean oil, may increase esophageal sensitivity to acid and influence the severity of reflux esophagitis (PMID 11911356, 22300015, 27716366) — a signal pointing toward risk rather than benefit. One completed trial testing fermented soybean supplementation for GERD (NCT06524271) is the closest to a direct therapeutic test, but it used a food supplement rather than pharmaceutical-grade soybean oil, was non-randomized/non-phased, and its relevance is graded only “B” (moderate).

Taken together, the evidence is directionally mixed rather than convergent: it does not clearly support a therapeutic mechanism for soybean oil in esophageal disease, and part of the literature raises a plausible risk signal instead.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT06524271	NA	Completed	110	Fermented soybean (FSB) supplementation tested for GERD symptom management; direct disease-relevant test but not a phased pharmaceutical RCT, and intervention is a food supplement, not soybean oil itself (relevance: B).
NCT05680064	NA	Completed	86	Chewing gum and tongue/lip/jaw exercises for xerostomia and dysphagia in Sjögren’s syndrome; addresses swallowing symptoms but has no direct relationship to soybean oil (relevance: C).
NCT03127345	Phase 2	Withdrawn (enrollment 0)	0	Compared omega-3 (Omegaven®) vs. standard soybean-based lipid emulsion (Intralipid®) on bone outcomes in infants with esophageal atresia; withdrawn before enrollment, no data generated (relevance: C).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
10024108	1999	RCT	Annals of Surgery	Soybean oil emulsion and EPA effects on stress response and immune function after esophageal cancer surgery — postoperative supportive care context, not disease treatment.
22457418	2013	RCT	JPEN J Parenter Enteral Nutr	Slow infusion of soybean oil emulsion and its effect on plasma cytokines/T-cell proliferation after esophagectomy.
22300015	2012	Cohort/Mechanistic	Neurogastroenterol Motil	Duodenal lipid intensifies esophageal acid perception via apolipoprotein A-IV/CCK signaling — suggests a symptom-provoking rather than protective role for fat.
24379010	2013	Cohort	Nutrients	Compared lipid emulsions (olive oil-based vs. MCT/LCT) in parenteral nutrition of esophageal cancer surgical patients; soybean oil not the primary comparator.
11911356	2002	Mechanistic	Dig Dis Sci	Intragastric fat infusion increased esophageal sensitivity to acid versus saline — a risk-direction mechanistic signal.
17868414	2007	Animal study	Cancer Science	High soybean-oil diet altered bile acid composition and promoted Barrett’s esophagus/adenocarcinoma development in a rat reflux model — potential harm signal.
27716366	2016	Animal study	Lipids Health Dis	n-3/n-6 PUFA ratio affected severity of acute reflux esophagitis in rats; direction depended on fatty acid ratio, not soybean oil alone.
9646301	1998	Review	Nutrition	n-3 vs n-6 PUFA effects on immune/metabolic outcomes in critical illness, including esophageal cancer patients; general nutritional review, not disease-specific.
31795982	2019	Case report	BMC Pulm Med	Case of exogenous lipoid pneumonia associated with avocado/soybean unsaponifiables, noting association with esophageal abnormalities/GERD; safety signal, not efficacy.
105637	1979	Cohort (historical)	Am J Hosp Pharm	Case of essential fatty acid deficiency during fat-free TPN in a patient with esophageal-colonic anastomosis obstruction; illustrates soybean oil’s role as an EFA source, not a treatment for esophageal disease.

South Africa Market Information

Soybean oil currently has no SAHPRA product registration under this evidence pack (0 licenses, market status: Not marketed).

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Note: safety data collection for this drug is currently blocked — no TFDA/SAHPRA package insert warnings or contraindications could be retrieved (data gap DG001, Blocking severity), so a safety pre-screen (S1 stage) cannot be completed until this is resolved.

Conclusion and Next Steps

Decision: Hold

Rationale:

Mechanism of action data is entirely absent, and the available literature on soybean oil and esophageal disease points in inconsistent directions — some studies suggest dietary fat may worsen esophageal acid sensitivity and reflux, while supportive-care studies only examine postoperative immune outcomes rather than disease treatment. No completed Phase 2/3 trial directly tests soybean oil for an esophageal indication, and the drug has no SAHPRA registration or market presence in South Africa.

To proceed, the following is needed:

TFDA/SAHPRA package insert warnings and contraindications (blocking gap, DG001) — required before any safety pre-screen
Mechanism of action data via DrugBank (DG002)
A dedicated mechanistic study clarifying whether soybean oil-derived lipids are protective or provocative for esophageal disease, given the conflicting literature signals
Confirmation of pharmaceutical-grade formulation and regulatory pathway, since the drug is currently unregistered in South Africa
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.